MRVI - Maravai LifeSciences Holdings Inc. (MRVI) Q1 2024 Earnings Call Transcript
2024-05-08 20:59:08 ET
Maravai LifeSciences Holdings, Inc. (MRVI)
Q1 2024 Earnings Conference Call
May 8, 2024, 5:00 PM ET
Company Participants
Debbie Hart - Head, Investor Relations
Trey Martin - Chief Executive Officer
Kevin Herde - Chief Financial Officer
Drew Burch - President, Nucleic Acid Production
Becky Buzzeo - Chief Commercial Officer
Conference Call Participants
Matt Hewitt - Craig-Hallum
Tejas Savant - Morgan Stanley
Dan Leonard - UBS
Tom Peterson - Baird
Matt Larew - William Blair
Bob Yan - Bank of America Securities
Presentation
Operator
Good day, ladies and gentlemen. And welcome to the First Quarter 2024 Maravai LifeSciences Earnings Conference Call. As a reminder, this call is being recorded. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session where participants are requested to limit themselves to one question and one follow-up. [Operator Instructions]
Thank you. I would like to now turn the call over to Debbie Hart, Head of Investor Relations. You may begin.
Debbie Hart
Good afternoon, everyone. Thanks for joining us on our first quarter 2024 earnings call. Our press release and the slides that accompany today’s call are posted on our website and available at investors.maravai.com.
As you can see on our agenda for today on Slide 2, Trey will first provide you with a business update; and Kevin will review our financial results and guidance. Drew Burch, President of Nucleic Acid Production; and Becky Buzzeo, our Chief Commercial Officer, will join the call for the question-and-answer session following the prepared remarks.
During today’s call, management will make forward-looking statements and refer to GAAP and non-GAAP financial measures. It is possible that actual results could differ from management’s expectations.
We refer you to Slide 3 for more detail on forward-looking statements and our use of non-GAAP financial measures. Our just-issued press release provides reconciliations to the most directly comparable GAAP measures. Please also refer to Maravai’s SEC filing for additional information on the risks and uncertainties that may impact our operating results, performance and financial condition.
Now I’ll turn the call over to Trey.
Trey Martin
Thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today. Let me briefly recap the quarter, highlight some innovative new products we are introducing and provide a few business updates before turning the call over to Kevin....
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2024 Earnings Call Transcript